Member Login
  1. Stocks
    2. /
  2. Bausch Health Companies Inc. (NYSE: BHC)
    3. /

NYSE:BHC (Bausch Health Companies Inc.)

About BHC

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Bausch Health Companies Inc. (NYSE: BHC) Latest News

    The Motley Fool
    Investing

    Is Concordia Healthcare Corp. or Valeant Pharmaceuticals Intl Inc. the Better Buy?

    | Kay Ng

    Investors could potentially make huge gains from Concordia Healthcare Corp. (TSX:CXR)(NYSE:CXRX) and Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), but which is…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Why Analysts Still Have a +$90 Price Target

    | Benjamin Sinclair

    Analysts still are very bullish on Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). Is something else going on here?

    Read more »

    The Motley Fool
    Investing

    The Epic Collapse of Valeant Pharmaceuticals Intl Inc. Continues

    | Demetris Afxentiou

    Shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) have now fallen nearly 50% in the past week, prompting many investors to…

    Read more »

    The Motley Fool
    Investing

    Can Valeant Pharmaceuticals Intl Inc. Dig Itself out of its Financial Hole?

    | Benjamin Sinclair

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is in danger of defaulting on its debt.

    Read more »

    The Motley Fool
    Investing

    Sell and Avoid Valeant Pharmaceuticals Intl Inc.

    | Jacob Donnelly

    Because of negative situations, investors should flee Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and avoid it for good.

    Read more »

    The Motley Fool
    Investing

    Why Bill Ackman Makes Valeant Pharmaceuticals Intl Inc. Shareholders Nervous

    | Benjamin Sinclair

    Pershing Square may have to sell shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), driving the shares down further.

    Read more »

    The Motley Fool
    Investing

    Why My Price Target for Valeant Pharmaceuticals Intl Inc. Is $0

    | Benjamin Sinclair

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) should not be bought at any price.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: 3 Things to Look for as it Reports 4th-Quarter Numbers

    | Benjamin Sinclair

    After two delays, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) will finally report fourth-quarter results on Tuesday.

    Read more »

    The Motley Fool
    Investing

    Why Are Valeant Pharmaceuticals Intl Inc. Shares Surging?

    | Benjamin Sinclair

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares are flying high. What is going on?

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Why the SEC Investigation Is a Very Big Deal

    | Benjamin Sinclair

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has a serious problem on its hands.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: A Timeline of the Monday Nightmare

    | Benjamin Sinclair

    Why did Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) fall more than 18% on Monday?

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Is Under Scrutiny From the SEC

    | Benjamin Sinclair

    The list of problems grows for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

    Read more »